Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V-POINT: Vonoprazan vs proton-pump inhibitor after gastric ESD under antithrombotic therapy
jRCTs041200045Completed
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in gastric adenoma and gastric cancer (GC) comparing Vonoprazan with Esomeprazole (2 arms). Primary endpoint: Incidence of bleeding within 8 weeks after ESD. Started Sep 2020; status: completed.
02
Drugs
vonoprazanesomeprazole
03
Conditions
gastric adenomagastric cancer (GC)
Beyond the preview
Go deeper on jRCTs041200045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200045.